Teva signs exclusive licence agreement for Biolojic’s BD9 multibody
Teva will obtain exclusive worldwide rights to develop and commercialise Biolojic’s BD9, a multibody designed as a multi-specific…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
15 Dec 23
Teva will obtain exclusive worldwide rights to develop and commercialise Biolojic’s BD9, a multibody designed as a multi-specific…
15 Dec 23
FoundationOne CDx and FoundationOne Liquid CDx are the company’s tissue-based and liquid-based comprehensive genomic profiling tests
15 Dec 23
The approval is based on the results of a multi-site, single-arm, externally controlled trial in which the addition…
15 Dec 23
This Sciex quadrupole time-of-flight high-resolution mass spectrometer is dedicated to GLP/GCP quantitation of oligonucleotide therapeutics and the planned…
14 Dec 23
Tarlatamab is an investigational, delta-like ligand 3 (DLL3) targeting Bispecific T-cell Engager (BiTE) therapy intended for the treatment…
14 Dec 23
The system includes a hollow-fibre module and draw solution for organic solvents to optimise the manufacturing processes in…
PharmaceuticalsActive Pharmaceutical Ingredients and Intermediates
14 Dec 23
The fourth generation BDTX-1535 is an oral, brain-penetrant, covalent EGFR inhibitor, which is currently in Phase 1 clinical…
14 Dec 23
Vertex Pharmaceuticals to obtain a non-exclusive license for Cas9 for CASGEVY
13 Dec 23
The acquisition will strengthen AstraZeneca’s vaccines and immune therapies pipeline with Icosavax’s lead investigational vaccine candidate IVX-A12, a…
13 Dec 23
The collaboration is aimed at developing new gene therapies for undisclosed CNS diseases by leveraging JCR Pharmaceuticals' proprietary…